Literature DB >> 12521561

Botulism.

Larry E. Davis1.   

Abstract

Botulinum toxin is the most potent toxin known to humans and as little as 100 ng can be lethal. The toxin blocks peripheral cholinergic neurotransmission at the neuromuscular junction and cholinergic autonomic nervous system by introducing an endopeptadase enzyme into the presynaptic side of the synapse. The endopeptadase cleaves acetylcholine vesicle docking proteins that are required for the synapse to release acetylcholine into the synaptic cleft. Botulism occurs from consumption or inhalation of preformed botulinum toxin or growth of Clostridium botulinum bacteria in the infant gastrointestinal tract or within a wound. Growth of C. botulinum in the immature gut or wound will release botulinum toxin that reaches the circulation. All forms of botulism cause progressive weakness, bulbar signs (blurred vision, diplopia, mydriasis, dysphagia, and dysarthria), and respiratory failure with normal sensation and mentation. Treatment is aimed at 1) maintaining respiration via intubation and mechanical ventilation, 2) stopping progression of weakness by administration of botulinum antitoxin (equine trivalent botulinum antitoxin for adults and botulism immune-globulin intravenous-human for infant botulism), and 3) preventing complications from weeks of paralysis with good supportive care. The source of the botulinum toxin should be identified to prevent additional cases. Patients can recover normal muscle strength within weeks to months, but usually complain of fatigue for years.

Entities:  

Year:  2003        PMID: 12521561     DOI: 10.1007/s11940-003-0020-1

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  18 in total

Review 1.  Infant botulism.

Authors:  S S Long
Journal:  Pediatr Infect Dis J       Date:  2001-07       Impact factor: 2.129

Review 2.  Clinical spectrum of botulism.

Authors:  M Cherington
Journal:  Muscle Nerve       Date:  1998-06       Impact factor: 3.217

Review 3.  Botulinum toxin: chemistry, pharmacology, toxicity, and immunology.

Authors:  M F Brin
Journal:  Muscle Nerve Suppl       Date:  1997

Review 4.  Botulinum toxin. From poison to medicine.

Authors:  L E Davis
Journal:  West J Med       Date:  1993-01

5.  Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases.

Authors:  K P Bhatia; A Münchau; P D Thompson; M Houser; V S Chauhan; M Hutchinson; A H Shapira; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

6.  Wound botulism in California, 1951-1998: recent epidemic in heroin injectors.

Authors:  S B Werner; D Passaro; J McGee; R Schechter; D J Vugia
Journal:  Clin Infect Dis       Date:  2000-10-25       Impact factor: 9.079

7.  Hypersensitivity reactions associated with botulinal antitoxin.

Authors:  R E Black; R A Gunn
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

Review 8.  Botulism in the United States: a clinical and epidemiologic review.

Authors:  R L Shapiro; C Hatheway; D L Swerdlow
Journal:  Ann Intern Med       Date:  1998-08-01       Impact factor: 25.391

9.  Patient recovery from type A botulism: morbidity assessment following a large outbreak.

Authors:  J M Mann; S Martin; R Hoffman; S Marrazzo
Journal:  Am J Public Health       Date:  1981-03       Impact factor: 9.308

Review 10.  Wound botulism in a patient with a tooth abscess: case report and review.

Authors:  J T Weber; H C Goodpasture; H Alexander; S B Werner; C L Hatheway; R V Tauxe
Journal:  Clin Infect Dis       Date:  1993-05       Impact factor: 9.079

View more
  3 in total

1.  Wound botulism from heroin skin popping.

Authors:  Larry E Davis; Molly K King
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

2.  Mysterious dysphagia.

Authors:  M J P Biggs; C A Quick
Journal:  J R Soc Med       Date:  2003-11       Impact factor: 18.000

3.  A label free colorimetric assay for the detection of active botulinum neurotoxin type A by SNAP-25 conjugated colloidal gold.

Authors:  Jennifer Halliwell; Christopher Gwenin
Journal:  Toxins (Basel)       Date:  2013-08-06       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.